Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary ...

Given as a once-weekly injection under the skin using a pre-filled syringe or pen, marstacimab is also the first haemophilia B treatment that works by targeting a protein in the blood clotting process ...

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency TA1064 22 May 2025 22 May ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...

Comparator companies Ipsen (somatropin) (confidentiality agreement not signed, not participating) Lilly (somatropin) (confidentiality agreement not signed, not participating) Merck Serono (somatropin) ...

Anxiety: Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care Clinical guideline Reference number: ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Suggested remit: To appraise the clinical and cost effectiveness of durvalumab within its marketing authorisation for induction and maintenance treatment of untreated advanced or recurrent endometrial ...

01 May 2024 Awaiting development. NICE will be undertaking an managed access review of Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high ...

The meeting will take place via Zoom, a secure web conferencing tool. You will need to join the meeting by 10:00am and it is expected to finish at approximately 3:00pm, although this may be subject to ...